Advances in treatment and prevention of hepatitis B

Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav

ORCID number: Niraj James Shah 0000-0003-4537-7859; Mark M Aloysius 0000-0001-6191-0524; Neil Rohit Sharma 0000-0001-8567-5450; Kumar Pallav 0000-0002-1322-3639.

Author contributions: Shah NJ, Aloysius MM, Sharma NR, and Pallav K performed the conception and design of the review article, acquisition of material, analysis and interpretation of material, critical revision, drafting the article, revising the paper, and its final approval.

Conflict-of-interest statement: All authors deny conflict of interest of any nature related to the article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/License s/by-nc/4.0/

Manuscript source: Invited manuscript

Specialty type: Gastroenterology

Abstract

Chronic hepatitis B (CHB) continues to contribute to worldwide morbidity and mortality significantly. Scientists, clinicians, pharmaceutical companies, and health organizations have dedicated substantial Intellectual and monetary resources to finding a cure, increasing immunization rates, and reducing the global burden of CHB. National and international health-related organizations including the center for disease control, the national institute of health, the American Association for the study of liver disease (AASLD), The European association for the study of the Liver (EASL), The Asia Pacific association for the study of the Liver (APASL) and the world health organization release periodic recommendations for disease prevention and treatment. Our review of the most recent guidelines by EASL, AASLD, APASL, and Taiwan Association for the Study of the Liver revealed that an overwhelming majority of cited studies were published before 2018. We reviewed Hepatitis B-related literature published 2018 onwards to identify recent developments and current barriers that will likely direct future efforts towards eradicating hepatitis B. The breakthrough in our understanding of the hepatitis B virus life cycle and resulting drug development is encouraging with significant room for further progress. Data from high-risk populations, most vulnerable to the devastating effects of hepatitis B infection and reactivation remain sparse. Utilization of systems approach, optimization of experimental models, identification and validation of next-generation biomarkers, and precise modulation of the human immune response will be critical for future innovation. Within the foreseeable future, new treatments will likely complement conventional therapies rather than replace them. Most Importantly, pragmatic management of CHB related population health challenges must be prioritized to...
produce real-world results.

Key Words: Chronic hepatitis B; Hepatitis B virus; Hepatitis B prevention; Hepatitis B treatment; Hepatitis B vaccination; Hepatitis B reactivation

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Given the hepatitis B viral life cycle’s unique characteristics, a true cure is lacking. Most recent guidelines from multiple societies including the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, Asia Pacific Association for the Study of the Liver, and Taiwan Association for the Study of the Liver, primarily include data published before 2018. A significant amount of hepatitis B relevant literature has been published since 2018. Our manuscript aims to review the recent literature for new developments and to identify the global strategies and knowledge gaps that will soon shape the scientific endeavor in this field.

INTRODUCTION

Hepatitis B virus (HBV) has infected humans for at least the past 40000 years[1] and is the 10th leading global cause of death[2]. HBV is the only DNA-based hepatotropic virus that exerts many adverse effects on the infected cells leading to necroinflammation, fibrosis, and carcinogenesis[3]. The world health organization (WHO), in 2015 has estimated 257 million people infected with chronic hepatitis B (CHB), while 887000 died from complications of hepatitis B[4]. Worldwide approximately only 10% of the patients with CHB are aware of the infection. A better understanding of hepatitis B biology, laboratory tests, and the immunological response has helped us develop vaccines and nucleoside/nucleotide analogs (NAs) to reduce new infection rates and achieve virologic suppression[5]. An overwhelming majority of studies cited in the most recent guidelines from various societies were published before 2018[6-10]. Our manuscript aims to review the recent literature for new developments and to identify the global strategies and knowledge gaps that will soon shape the scientific endeavor in this field.

METHODS

Literature search: We conducted online electronic searches (published human clinical trials in English) of the National Library of Medicine (Bethesda, MD, United States) MEDLINE database, Cochrane Library, and manual searches of selected specialty journals to identify any pertinent literature. We searched three MEDLINE databases (Ovid, PubMed, and EMBASE) using the following keywords hepatitis B, prevention of hepatitis B, hepatitis B and co-infection, management of hepatitis, hepatitis B and transplantation, hepatitis B mortality, hepatitis B vaccination, hepatitis B reactivation, systematic review for hepatitis B, meta-analysis and hepatitis B. The references of articles were reviewed for additional articles.

Inclusion criteria: Articles describing original research and high-quality review articles published within the last three years were selected. The search was focused on hepatitis B articles published in 2018 or later.

Exclusion criteria: Articles that did not contribute significantly to research and scientific knowledge after 2018 were excluded.
Serological markers for hepatitis B infection

The serologic patterns of chronic HBV infection are varied and complex. Antigens and antibodies associated with HBV infection include hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs), hepatitis B core antigen (HBcAg) and antibody to HBcAg (anti-HBc), and hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe). Testing also can be performed to assess the presence and concentration of circulating HBV DNA. At least one serologic marker is present during each of the different phases of HBV infection. Serologic assays are commercially available for all markers except HBcAg, because no free HBcAg circulates in blood[11] (Table 1).

There is overwhelming evidence that antiviral therapy reduces mortality, and risk of hepatocellular carcinoma (HCC) and improves intermediate prognosis, and overall health outcomes. As such, the most recent document from the United States Preventive Service Task Force recommends screening for hepatitis B in adolescents and adults at increased risk of HBV, with HBsAg tests approved by the United States Food and Drug Administration, followed by a confirmatory test for initially reactive results[12].

A positive HBsAg result indicates chronic or acute infection. Screening recommendations for special populations include initial testing with anti-HBs and or anti-HBc in addition to HbsAg[10]. Serologic panels performed concurrently with or after HBsAg screening allow for diagnosis and to determine further management[12].

Serological markers are critical for monitoring treatment response and predicting complications. The primary endpoint for treatment is durable HBsAg loss (functional cure) based on assays with a lower detection limit (LLLOD-0.05 IU/mL) with or without HBsAg seroconversion and undetectable serum HBV DNA after completing a course of treatment[13].

Zhang et al[14] published in 2018, results from a multicenter trial, assessing kinetics of HBsAg in 1795 HBV patients[14]. The HBsAg titers were significantly higher (P < 0.0001) in patients with HBeAg positive HBV than HBeAg negative HBV patients. They demonstrated that in patients with positive HBeAg, the HBsAg titers were inversely proportional to fibrosis, while alanine aminotransaminase (ALT) and necro-inflammatory activity were directly correlated with HBsAg titers in HBeAg negative HBV patients[14].

Biomarkers for HBV functional cure include HBsAg clearance profile (CPs, defined by loss of binding at both loops 1 and 2 epitopes of the ‘a’ determinant)[15]. A 48th week and 192th week HBsAg CPs analysis of genotype A CHB patients on either tenofovir or adefovir for at least four years prior revealed its positive association with HBsAg loss (SL), seroconversion, and response to treatment[15].

For most patients with CHB who do not achieve a functional cure, long-term NA is likely needed. Despite long-term therapy, liver-related complications can still occur even with sustained viral suppression. To this end, newer virological markers were developed to predict the risk of liver-related complications in these patients who often have undetectable serum HBV DNA, and the likelihood of achieving a functional cure, which is defined as off-therapy virological suppression[16].

The covalently closed circular DNA (cccDNA) protein is a template used for transcription and subsequent translation of viral proteins. The persistence of cccDNA within the nucleus of infected hepatocytes despite treatment and viral suppression is the underlying mechanism for infection reactivation after treatment cessation[17]. Of the various viral proteins synthesized, the hepatitis b core-related antigen (HBcrAg) is a combination of three related viral proteins (HBcAg, HBeAg, and a truncated 22kDa precore protein)[18,19]. HBcrAg has a superior correlation to the decline in HBV DNA levels with antiviral therapies, and with intrahepatic HBV cccDNA levels[20-22]. It is also helpful in predicting HBV reactivation in immunosuppressed individuals and the development of HCC[24-28]. Another relatively novel biomarker, HBV RNA is a pregenomic RNA containing virion similar to HBcrAg[16]. Treatment naive patients with CHB have lower serum levels (lower by 1-2 logs) of HBV RNA when compared to HBV DNA serum levels[29,30]. However, in patients receiving NA’s, the HBV RNA levels are significantly higher than HBV DNA and hence it is a predictor of response. HBV RNA has a strong linear correlation with both HBV DNA and HBsAg titers[31,32]. Both, HBcrAg and HBV RNA, can predict long-term off-therapy HBV virological control in patients treated with NA’s[29,33]. A recent prospective trial by Chang et al[34] confirmed HBcrAg levels to reflect on-treatment hepatic fibrosis progression, and hence its role in monitoring hepatic histological changes[34]. Liao et al[35] demonstrated the utility of monitoring of HBV RNA and HBcrAg levels for NA-treated patients with undetectable HBV DNA and undetectable HBV RNA occurring before HBcrAg undetectability[35].
Multiple challenges must be met before these biomarkers can be fully utilized in clinical practice. The specific methods and technical details of serum RNA detection vary widely between different studies and standardization of such is urgently needed [16]. To exclude interference from viral DNA, methods for measuring pgRNA usually require a selective DNA degradation step, which is complicated and time-consuming and also compromises the accuracy of detection[36]. Further research is needed to determine specific cutoff values of HBcrAg to determine clinical outcomes and determine the role of HBV RNA in occult hepatitis B infection, HbsAg seroclearance, HBV reactivation, and development of Hepatocellular Carcinoma[24-28]. Additionally, the biomarkers will need to be validated in different racial and ethnic populations. Studies correlating novel biomarkers with hepatic fibrosis and cccDNA require serial liver biopsies, resulting in reduced sample sizes. In a recent trial, Brakenhoff et al. [37] showed that HBV RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. This study highlighted the need for future trials that consider the kinetics of combined biomarkers to assess antiviral efficacy[37].

**HEPATITIS B VACCINATION**

Current recommendations advocate pre-exposure universal vaccination for newborns and non-immune individuals who are at a high risk of exposure or have a poor disease outcome [patients with hepatitis C virus infection, human immunodeficiency virus (HIV), men who have sex with men, intravenous drug users, health care workers, and household contacts of patients with a positive hepatitis surface antigen][38,39]. Until 2017, most available HBV vaccination schedules required three doses of the vaccine to be administered at specific intervals and had > 90% protective response[40].

On November 9, 2017, Heplisav-B (HepB-CpG), a single-antigen HepB vaccine with a novel immunostimulatory sequence adjuvant, was approved by the Food and Drug Administration for the prevention of HBV in persons aged ≥ 18 years[41]. The vaccine is administered in two doses, one month apart. On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP)* recommended HepB-CpG for use in persons aged ≥ 18 years[42].

Unfortunately, 5%-10% of patients lack an immunological response and remain unprotected despite vaccination[43]. A hepatitis B “non-responder” refers to a person...
who does not develop Hepatitis B surface antibodies after completing two whole series of hepatitis B vaccine and for whom an acute or CHB infection has been ruled out. Non-response is associated with different HLA-DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. For non-responders to the initial vaccination series, a second series of the original vaccination schedule is recommended. Persons with Hepatitis B surface antibody (anti-HBs) < 10 mIU/mL following receipt of 2 doses of HepB-CpG should be revaccinated with a second complete HepB vaccine series followed by anti-HBs testing 1-2 mo after the final dose. Alternatively, revaccination may consist of administration of an additional single HepB vaccine dose followed by anti-HBs testing 1-2 mo later (and, if anti-HBs remains < 10 mIU/mL, completion of the second HepB vaccine series followed again by anti-HBs testing 1-2 mo after the final dose). Post-exposure prophylaxis should be considered for individuals following a needlestick injury or potentially infectious exposure to body fluids with blood or semen.

Recent studies evaluating the efficacy of alternate revaccination regimens in non-responders are promising and could shape future recommendations. Raven et al. studied 480 immunocompetent, non-responders in a multicenter, open-labeled, randomized, controlled superiority trial comparing the effectiveness of revaccination with initial regimen (control arm: With HBVaxPro 10 μg or Energix B 20 μg) vs three alternate regimens (Twinrix 20 μg or Fendrix 20 μg, or HBVaxPro 40 μg). Revaccinating with Fendrix 20 μg (83%) or HBVaxPro 40 (98%) resulted in significantly higher proportions of responders compared to controls (67%). Authors argued that the indication for these vaccines should be expanded to enable revaccination of non-responders. In 2018, Ko et al. attempted to enhance the immune response of the HBVaxPro®-10-μg vaccine by adding a cytokine-based adjuvant. This new adjuvant AI20, containing 20-μg recombinant human Interleukin (IL)-2 attached to 20-μg aluminum hydroxide, was added to HBVaxPro®-10-μg (HBAl20). In an open-label trial, HBAI20 elicited protective anti-HBs titers in 90% of previous non-responders.

Additionally, researchers have turned to “Systems vaccinology” to precisely understand vaccine mechanisms and potential determinants of immunological non-response. Technological advances with DNA microarrays and high throughput DNA sequencing, mass spectrometry powered proteomics, bioinformatics, and computational methods enable data integration that serves as the basis of systems vaccinology. Qiu et al. performed transcriptome and cytokine analysis of seven responders and seven non-responders pre-and post-vaccination with a three-dose boost regimen. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and, TKTL1) were significantly upregulated in non-responders, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. This probability was further strengthened by gene ontology analysis results showing that most of these differentially expressed genes were related to immune response. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders. In multiplex cytokine assay, IL-27 and CXCL12 may probably act as the characteristic cytokine marker for responders. Da Silva et al. demonstrated a reduced baseline CXCR3+CCR6- CXCR5+ memory T cells, contributing to impaired seroconversion with vaccination in patients with chronic kidney disease (CKD). The authors further suggested an augmented 40-μg HBV dose schedule for CKD (comparable to hemodialysis patients) rather than the 20-μg dose suggested by the center for disease control (CDC).

Booster doses are not indicated in immunocompetent individuals if the primary vaccination series is complete, as long-term follow-up studies show that immune memory persists despite declining hepatitis B surface antibody (anti-HBs) levels. In a recent prospective trial published in 2019, 101 adults vaccinated with recombinant hepatitis B vaccine 20-30 years prior, were challenged with a dose of HBSAg vaccine. 100% of patients developed an anamnestic response by day 30 with a significant increase in HBSAg-specific memory B and CD4+T cells expressing at least two activation markers. These results align with current knowledge and suggest sustained immune memory and long-term protection 20-30 years after a complete primary HBSAg vaccination course during adulthood.

Specific immunocompromised populations present an exception to this rule. One such population is patients undergoing bone marrow transplant. In this respect, the American Association for the study of liver disease (AASLD) guidelines are informed by the "Recommendation of the ACIP" document published in January 2018. The document suggests that the humoral response to the hepatitis B vaccine is reduced in...
children and adults who are immunocompromised (e.g., hematopoietic stem cell transplant recipients, patients undergoing chemotherapy, and HIV-infected persons) [60,61]. Modified dosing regimens, including a doubling of the standard antigen dose or administration of additional doses, might increase response rates. However, data on response to these alternative vaccination schedules is limited [62].

Chawansuntti et al [63] showed a reduced tumor necrosis factor (TNF)-α and IL-2 Level from CD4+ T cells in HIV-infected patients receiving standard HBV vaccinations and suggested an increased dose or frequency to counter this problem [63].

In 2018, Palazzo et al [64] published the results of a prospective study assessing the safety and efficacy of revaccination in 122 multiple myeloma patients on maintenance dose Lenalidomide post autologous hematopoietic stem cell transplantation. The efficacy of revaccination was determined by comparing pre-and post-vaccination antibody titers. Their data suggested absolute safety and 40% efficacy in those receiving the Hepatitis B vaccine (Twinrix, GlaxoSmithKline, London) [64].

Surprisingly, the development of HBV reactivation following hematopoietic stem cell transplant (HSCT) can occur despite successful revaccination and maintenance of serum anti-HBs at more than protective levels. Nishikawa et al [65] in 2020, published their results from a prospective trial studying vaccination to prevent HBV reactivation after hematopoietic stem cell transplantation [65]. The authors showed that of the 27 patients vaccinated 12 mo after HSCT and monitored for two years, six showed HBV reactivation, with a 2-year cumulative reactivation incidence of 22.2%. Factors associated with HBV reactivation included the discontinuation of immunosuppressants (P = 0.0379) and baseline titers of anti-HBs (P = 0.004) [65]. Nucleic acid-based vaccine for HBV prevention is a novel approach but yet to show effectiveness in generating a sustained immune response in clinical trials [66] (Table 2).

**HEPATITIS B TREATMENT**

**Per** the 2018 updates to the AASLD guidelines, patients with CHB (Persistence of HBsAg > six months) should be considered for treatment if the ALT > 2 ULN and patients are HBeAg positive with HBV DNA > 20000 or HBeAg Negative with HBV DNA > 2000. Approved therapies are limited to single-drug regimens, including Nucleoside/Nucleotide reverse transcriptase inhibitors and pegylated Interferon (PEG-IFN). Approved regimens are divided into preferred [PEG-IFN, Entecavir (ETV), tenofovir fumarate, and tenofovir alafenamide (TAF)] and Non-Preferred [Lamivudine, Adefovir, Telbivudine] [10].

Multiple recently published studies support the recommendations in demonstrating the safety and efficacy of IFN and Tenofovir over the non-preferred drugs.

Chuang et al [67] demonstrated sustained HBeAg seroconversion rates of 67.1%, five years after completion of the NEPTUNE trial, with a PEG-IFN dose of 180 μg/wk for 48 wk suggesting that the licensed regimen (180 μg × 48 wk) is more efficacious for HBeAg-positive patients than a lower dose and/or shorter treatment duration [67]. A 96-week HBV viral suppression for patients treated with both TAF, a prodrug of tenofovir disoproxil fumarate (TDF), and TDF, were comparable at 73% vs 75% and 90% and 91%, for HBeAg positive and HBeAg negative patients respectively [68]. A prospective randomized controlled trial (RCT) by Yim et al [69] studying partial responders to ETV (defined by detectable HBV DNA > 60 IU/mL), continuing ETV vs switching to TDF, revealed a statistically significant 12-mo HBV virological response (P = 0.022) in the subgroup that was switched to TDF [69]. In another prospective trial, stable switching to TDF monotherapy yielded non-inferior results at 96 wk compared to Lamivudine + Adefovir combination therapy in patients with Lamivudine resistant CHB and non-detectable HBV DNA [70]. Marcellin et al [71] published a 10-year efficacy (HBV suppression in 100% of HBeAg-negative and 98% in HBeAg positive patients) and safety data (few renal or bone-related adverse events, with no resistance) with tenofovir fumarate treatment for CHB virus infection in 585 patients (203 completed the 10-year study) [71]. A large, multicenter RCT, published in January 2019, including 320 treatment Naive HBeAg positive patients showed that after long term treatment (144 wk), both tenofovir fumarate and ETV suppressed HBV DNA similarly (ETV vs TDF; -6.6485 vs -6.692 log 10 IU/mL, P = 0.807) and had similar serologic, biochemical, and side-effect profiles [72]. Recent encouraging data from a 104-wk prospective study on treatment of naive HBeAg positive patients treated with telbivudine-based therapy shows a reduction in liver stiffness (monitored by Fibroscan®), from 8.6 at baseline to 6.1 at week 24, and 5.3 at week 104 [73].
Table 2 Studies addressing hepatitis B vaccination strategies

| Ref. | Study type | Main findings |
|------|------------|---------------|
| Koc et al[49], 2018 | Prospective open label trial | HBA20 (HBVaxPro®-10-μg vaccine combined with an adjuvant Al20, a recombinant human IL-2) exhibited protective anti-HBs titers in 90% of previous non-responders likely due to an enhanced immune response |
| Qiu et al[53], 2018 | Prospective trial | Genome wide comparative analysis revealed significant transcriptome and cytokine changes in HBV vaccine non-responders |
| Da Silva et al[54], 2018 | Randomized prospective trial | Impaired seroconversion for HBV vaccination in CKD patients was linked to reduced baseline CXCR3 + CCR6- CXCR3+ memory T cells levels |
| Van Damme et al[59], 2019 | Prospective trial | Immune challenge, in previously vaccinated adults (HBsAg vaccine 2-3 decades prior) showed a 100% anamnestic response by day 30 with significant increase in HBsAg-specific memory B and CD4+ T cells |
| Raven et al[48], 2020 | Open-labeled, randomized, controlled superiority trial | In Immunocompetent non-responders, revaccination with Fendrix 20 μg or HBVaxPro 40 μg resulted in significantly higher response rates compared to HBVaxPro 10 μg, Energix B 20 μg, or Twinrix 20 μg |
| Chawansuntati et al[63], 2018 | Prospective trial | HBV patients with HIV co-infection have reduced levels of TNF-α and IL-2 levels, and may require an increased HBV vaccine dose to counter this problem |
| Palazzo et al[64], 2018 | Prospective trial | Revaccination with the Hepatitis B vaccine (Twinrix, GlaxoSmithKline, London), in HBV patients on maintenance Lenalidomide post autologous hematopoietic stem cell transplant was absolutely safe with 40% efficacy |
| Nishikawa et al[65], 2020 | Prospective trial | For HBV vaccinated, HSCT recipients, 2-year and 3-year cumulative HBV reactivation rates were 22.2% and 28.9% respectively. Discontinuation of immunosuppressants (P = 0.0379) and baseline titers of anti-HBs (P = 0.004) were related to HBV reactivation |

IL-2: Interleukin 2; anti-HBs: Anti Hepatitis B surface antibody; HBsAg: Hepatitis B surface antigen; HIV: Human Immunodeficiency virus; HBV: Hepatitis B virus; TNF: Tumor necrosis factor; HSCT: Hematopoietic stem cell transplant; CKD: Chronic kidney disease.

Despite the efficacy and safety of current regimens in achieving viral suppression, reactivation is, unfortunately, the norm after treatment cessation due to the persistence of cccDNA[74]. Recent studies further highlight this serious shortcoming.

The Toronto STOP study evaluated 67 HBV patients who achieved HBeAg seroconversion and undetectable HBV DNA after treatment with a NA. Patients were then randomly selected to discontinue. Sustained virological remission was maintained in only 29% of patients who stopped the treatment vs 82% of patients who continued NA[75]. Buti et al[76] studied the safety and efficacy of discontinuing HBV treated (with TDF) patients after eight years of therapy. At 24 wk following discontinuation of NA, almost a third of patients had grade 3 hepatotoxicity (indicated by aspartate aminotransferase/ALT of > 5 - < 10 ULN, and total bilirubin of > 3 - < 10 ULN)[76].

In another follow-up study of a phase 2 trial at two centers, Immune-tolerant patients with CHB received TDF and/ or Emtricitabine for four years and were followed for another four years after cessation. The authors recorded a 100% virological relapse at week 4 (HBV DNA > 2000) and a 50% clinical relapse (HBV DNA > 2000 and ALT > 2 ULN) at 15 ± 11 wk[77].

Given the limitations noted by these studies, researchers have resorted to utilizing combination regimens with IFN and NA in hopes of improving seroconversion rates while others have attempted to determine predictors of response to develop a more targeted approach.

Liem et al[78], while looking for the optimal candidates that could benefit from a combination of PEG-IFN with nucleot(t)ide, prospectively evaluated HBeAg positive HBV patients treated with ETV. Randomized addition of PEG-IFN to ETV therapy was associated with a higher 48-week response rate (response defined as HBeAg loss), with a significant P = 0.03, compared to ETV monotherapy[78]. The HERMES Study Group published their results from a prospective RCT in 2019 showing that the addition of PEG-IFN alfa-2a (for 48 wk) to ongoing NA therapy significantly decreased HbsAg levels (defined by greater than 50% decline) in HBeAg-negative patients with genotype D infection[79].

In a recent prospective trial CHB patients who seroconverted on ETV, were switched to weekly PEG-IFN alfa-2a. The authors recorded an 88% sustained response in patients with a baseline HBsAg < 1500 IU/mL, while 50% of patients with a baseline HBsAg < 500 developing HbsAg loss[80]. The same group also validated data from 647 patients with HBeAg positive CHB on PEG-IFN alfa-2a to develop a pre-treatment scoring system using baseline factors like age, sex, alanine aminotransferase ratio, HbsAg level, and HBV DNA level to predict response to therapy[81].
A recently published large meta-analysis with 24 studies and 6674 subjects confirmed the importance of longer treatment duration and addition of IFN for HBsAg lowering and highlighted the potential value of immune-based therapies[82].

Recent identification of novel targets within the hepatitis B viral life cycle has led to the development of multiple therapeutic agents with varying mechanisms[83]. These include either direct inhibition of viral replication by targeting fundamental steps such as entry, cccDNA formation/stability, viral transcription, capsid assembly, and secretion or manipulating the host immune system for augmentation of innate and/or adaptive immunity[17]. The viral life cycle, resulting viral products, and their role in the pathogenesis of CHB is a rather broad and complex topic in and of itself. We found a recent article by Tsukuda et al[84] titled ‘Hepatitis B viral biology and life cycle’ to be an excellent resource for further information on this topic[84].

The discovery of the sodium taurocholate co-transport polypeptide (NTCP) (gene: SLC10A1) receptor as a gateway for HBV entry into hepatocytes was made approximately a decade ago[85]. The discovery has been a significant source of optimism, and NTCP has served as a target for developing viral entry inhibitors, including mycrocycline and cyclosporine[86,87]. Additionally, NTCP complemented stable cell lines, cell cultures, and infection model systems have allowed standardized research to understand better the HBV life cycle and development of therapeutic options[88-91]. By allowing the study of authentic infection in cell lines, these model systems have helped achieve a better understanding of the formation and degradation of cccDNA, a key target to achieve the ultimate goal of HBV cure[92,93]. National institute of health (NIH)-funded trials to target viral proteins required for viral entry into uninfected hepatocytes, viral replication targeting adaptive immunity (anti-programmed cell death-1) and innate immunity (anti-programmed death-ligand 1 antibodies, chimeric antigen receptor T cells), and silencing of cccDNA are underway[94]. A preclinical trial of cccDNA endonucleases (CRISPR/Cas9) showed a reduction in cccDNA, other viral gene expression parameters as well as replication in vitro[95]. Multiple recent trials have evaluated the safety and efficacy of Core Protein (Capsid) Assembly Modulators in patients suffering from CHB. In a phase 1 study of HBeAg-positive CHB patients without cirrhosis, NVR 3-778 was well tolerated and demonstrated antiviral activity. The agent reduced serum levels of HBV DNA and HBV RNA, to the greatest extent combined with PEG-IFN. The observed reductions in HBV RNA confirmed the novel mechanism of NVR 3-778 [96]. A phase I, randomized placebo-controlled trial published in Lancet in 2020, showed acceptable safety, pharmacokinetics, and antiviral effects on an investigational HBV core protein inhibitor ABI-H0731[97]. Another phase I trial, by Zhao et al[98], evaluated the safety, tolerability, and pharmacokinetics of GLS4 (a novel HBV capsid assembly inhibitor), with or without ritonavir (used to enhance plasma levels of GLS4) and was found to have acceptable tolerability and sustained higher than proposed effective plasma trough concentration, when used in combination[98]. A phase I double-blind, RCT of 30 healthy adults, by Vandenbossche et al[99], looked into the safety, tolerability, and pharmacokinetics of JNJ-56136379 (a novel HBV capsid assembly modulator), showed it to be well-tolerated, with a more than three times the 90% effective plasma concentration required to inhibit viral replication[99].

HBV regulatory protein X (HBx) was recently found to promote transcription from cccDNA through an interaction with a host protein DDB1[100]. Sekiba et al[101] applied a newly constructed split luciferase assay system to comprehensive compound screening to identify candidate compounds that targeted the HBX-DDB1 interaction and showed that nitazoxanide (NTZ), efficiently inhibits the HBX-DDB1 protein interaction. NTZ significantly suppressed viral transcription and viral protein production in human primary hepatocytes naturally infected with HBV[101]. Antisense oligonucleotides are small single-stranded nucleic acid sequences that bind selectively to their target RNAs and cause degradation[102]. GSK3389404 is a liver-targeted antisense oligonucleotide that inhibits the synthesis of HBsAg and all other HBV proteins. A recent randomized double-blind controlled phase 1 trial showed acceptable safety and pharmacokinetic profile, supporting further clinical investigation in patients with CHB[103].

The human immune system controls and clears adulthood-acquired hepatitis B in over 95% of patients[94]. A large body of data links suppressed T and B cell responses to persistent hepatitis B and liver injury[104-106]. Moreover, data from trials involving B and T cell responses strongly suggest that augmentation of immunity can clear the infection[107]. Therefore, boosting the magnitude and quality of the virus-specific immune response is a rational strategy for therapy[108]. Various toll-like receptor (TLR) agonists have shown promising antiviral effects in small prospective trials. GS-9620, a TLR-7, when administered for 12 wk, though did not significantly affect serum HBsAg levels. However, it did increase T-cell and NK-cell responses[109-111]. Han et
al.[112] demonstrated HBeAg positive CHB patients to have a lower baseline galactosylation level, and hence being suitable candidates for the use of HBsAg-hepatitis B immune globulin (HBIG) immune complex, administered as a therapeutic vaccine, to achieve HBeAg seroconversion. The marked-up regulation of IL-2 and galactosylation levels confirmed this to be an immune response[112].

The goal of therapeutic vaccination is to stimulate or boost the host immune response to restore immune control, leading to sustained suppression of HBV replication and ultimately HBsAg loss[13]. A recently published meta-analysis of 15 studies reviewed the evidence for therapeutic vaccines’ efficacy and safety in CHB patients[113]. The authors concluded by saying that therapeutic vaccines do not appear to be efficacious for the treatment of CHB but were limited by few RCTs, suboptimal therapeutic vaccines, and patient selection.

An open-label phase III trial comparing a therapeutic vaccine (NASVAC, containing 100 µg of each HBs and HBc antigens, administered in 2 cycles of 5 doses) vs PEG-IFN alfa 2b (180 µg every week for 28 wk in naive CHB patients showed significantly better controlled HBV DNA, 24 wk post-treatment (P < 0.05) and a lower rate of progression to cirrhosis in the NASVAC group[114]. HBsAg-based recombinant vaccines, administered every eight weeks for 48 wk, with a total of 7 doses, have been shown to reduce HBsAg levels (P = 0.0005) and achieve HBsAg seroconversion in 10.52% of the patients with low HBsAg titers[115]. A multicenter prospective phase 2 RCT by Boni et al.[116] demonstrated improved HBV specific T cell responses, including IFN-γ, TNF-α, and IL-2, with a combined GS-4774 (yeast-based engineered vaccine) and tenofovir vs tenofovir alone[116].

The HBV Endeavor prospective trial by Wu et al.[117] looked into switching HBV patients with confirmed viral suppression and HBsAg loss from nucleos(t)ide analogs to immunomodulators (IL-2) and therapeutic vaccines with IFN to enhance HBsAg loss to achieve HBV virological cure. HBsAg loss was documented to be 9.38%, 3.03%, and 3.7% in the IFN/vaccine/IL-2 group, IFN group, and the ETV group, respectively. The higher titers of CD16-NK cells and lower titers of regulatory T cells corresponded to higher response rates of HBsAg loss[117] (Table 3).

**HEPATITIS B SPECIAL POPULATIONS**

**Mother to child transmission of hepatitis B**

Antiviral therapy has been studied as an intervention to reduce perinatal HBV transmission amongst pregnant women with high HBV viral DNA levels[9,118,119]. All newborns born to HBV infected mothers should receive HBIG and HBV vaccine within 12 h of delivery followed by completion of 2 or 3 vaccine series[47]. AASLD suggests antiviral therapy starting at 28-32 wk to reduce perinatal HBV transmission when maternal HBV DNA is > 200000 IU/mL[9]. Tenofovir is recommended as the preferred agent due to lack of resistance and availability of safety data and the therapy is discontinued at some point between birth and three months postpartum[9].

Cressey et al.[120] assessed for the first time tenofovir exposure during pregnancy and postpartum in HBV-infected HIV-uninfected women receiving TDF to prevent mother-to-child transmission of HBV. They concluded that the modest reduction in tenofovir exposures observed during pregnancy does not warrant a dose adjustment[120].

At least two recent studies have demonstrated the safety and efficacy of the addition of TDF to standard newborn immune prophylaxis in reducing maternal to child transmission (MTCT) in pregnant women, with very high viral loads[121,122]. Alternatively, in a multicenter, double-blind clinical trial performed in Thailand, authors demonstrated that in a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission[123].

These studies reiterate the safety, efficacy, and practicality of Tenofovir in pregnant women at high risk for MTCT of hepatitis B. In their July 2020 guidelines on antiviral prophylaxis in pregnancy, WHO recommends that pregnant women testing positive for HBV infection (HBsAg positive) with HBV DNA ≥ 5.3 log10 IU/mL (≥ 200000 IU/mL) receive tenofovir prophylaxis from the 28th week of pregnancy until at least birth, to prevent mother-to-child transmission of HBV. This is in addition to three-dose hepatitis B vaccination in all infants, including timely birth dose[124].

In immune-tolerant (HBeAg positive) CHB patients awaiting assisted reproduction, an RCT conducted by Wu et al.[125] showed greater viral clearance (90% vs 67.2%, P =
In Lamivudine resistant HBV patients with non-detectable HBV DNA, 96-wk HBV suppression rates were comparable in patients treated with Meta-analysis Randomized addition of PEG-IFN to ETV therapy, in HBeAg positive PEG Interferon at a dose of 180 μg/wk for a duration of 48 wk resulted in Randomized controlled trial Prospective trial Pre-clinical prospective study HBV patients treated with TDF, and then discontinued: At 24 wk Prospective trial HBV treatment naïve HBeAg positive patients treated with Telbivudine-Prospective study A 10-yr TDF efficacy study showed HBV viral suppression in 100% of Multicenter randomized controlled trial Phase II prospective trial Demonstrated acceptable safety and pharmacokinetics of GLS4 (a novel Prospective randomized controlled trial Use of ccc DNA endonucleases (CRISPR/Cas9) resulted in a reduction in both ccc DNA and other parameters of viral gene expression and replication in vitro Pre-clinical prospective study Use of ccc DNA endonucleases (CRISPR/Cas9) resulted in a reduction in both ccc DNA and other parameters of viral gene expression and replication in vitro Phase I prospective trial Non-cirrhotic HBeAg-positive CHB patients, tolerated NVR 3-778 (a capsid assembly protein modulator), and showed reduced serum levels of HBV DNA and HBV RNA, to the greatest extent in combination with PEG-IFN Phase I, randomized placebo-controlled trial Demonstrated acceptable safety, pharmacokinetics, and antiviral effects on an investigational HBV core protein inhibitor ABI-H0731 Phase I, randomized controlled trial Demonstrated acceptable safety and pharmacokinetics of GLS4 (a novel HBV capsid assembly inhibitor), with or without ritonavir (used to enhance plasma levels of GLS4) Phase I double-blind, randomized Demonstrated acceptable safety and pharmacokinetics of JNJ-56136379 (a

| Ref.                  | Study type                              | Findings                                                                 |
|----------------------|------------------------------------------|--------------------------------------------------------------------------|
| Conventional treatment agents |                                         |                                                                          |
| Chuang et al[67], 2018 | Prospective study                        | PEG Interferon at a dose of 180 μg/wk for a duration of 48 wk resulted in better sustained HBeAg seroconversion rates, than in patients with a lower dose and/or shorter treatment duration |
| Agarwal et al[68], 2018 | Randomized controlled trial              | 96-wk HBV suppression rates were comparable in patients treated with TAF and TDF, for HBeAg positive (73% vs 75%) and HBeAg negative (90% vs 91%) patients |
| Yim et al[69], 2018    | Prospective randomized controlled trial  | HBV patients who were partial responders to ETV, fared better (12-mo HBV response, P = 0.022), when switched to TDF versus continuing ETV |
| Lee et al[70], 2018    | Prospective trial                        | In Lamivudine resistant HBV patients with non-detectable HBV DNA, while on Lamivudine + Adefovir combination therapy, switching to TDF monotherapy yielded non-inferior results at 96-wk |
| Marcellin et al[71], 2019 | Prospective trial                      | A 10-yr TDF efficacy study showed HBV viral suppression in 100% of HBeAg-negative and 98% in HBeAg positive patients, with few renal or bone-related adverse events, and no resistance to TDF |
| Cai et al[72], 2019    | Multicenter randomized controlled trial  | HBV treatment naïve HBeAg positive patients treated with ETV or TDF, showed similar HBV DNA suppression (-6.6485 vs -6.692 log 10 IU/mL, P = 0.807) at 144 wk as well as similar serologic, biochemical, and side-effect profiles |
| Liang et al[73], 2018  | Prospective trial                        | HBV treatment naïve HBeAg positive patients treated with Telbivudine-based therapy showed a reduction in liver stiffness, monitored by Fibroscan®, from 8.6 at baseline to 6.1 at week 24, and 5.3 at week 104 |
| Liem et al[75], 2019   | Randomized controlled trial              | In HBV patients who received NA, and achieved HBeAg seroconversion with undetectable HBV DNA, maintenance of remission was seen in 82% of those who continued NA vs 29% of those who discontinued NA |
| Buti et al[74], 2019   | Prospective trial                        | HBV patients treated with TDF, and then discontinued: At 24 wk following discontinuation of NA, almost a third of patients had grade 3 hepatotoxicity (indicated by AST/ALT of > 5 - < 10 ULN, and total bilirubin of > 3 - < 10 ULN) |
| Wong et al[76], 2018   | Phase II prospective trial               | HBV immune-tolerant patients who received TDF and/or Entecitabine for 4 yr and were followed for another 4 yr after cessation, showed 100% virological relapse at week 4 (HBV DNA > 2000) and a 50% clinical relapse (HBV DNA > 2000 and ALT > 2 ULN) at 15 ± 11 wk |
| Liem et al[78], 2019   | Randomized prospective trial             | Randomized addition of PEG-IFN to ETV therapy, in HBeAg positive HBV patients was associated with a significantly higher 48-wk response rate (HBeAg loss), compared to ETV monotherapy (P = 0.03) |
| Lampertico et al[79], 2019 | Prospective randomized controlled trial | Genotype D, HBeAg-negative HBV patients, on NA therapy showed a significant 50% decrease in HBsAg levels, with the addition of PEG-IFN alfa-2a for 48 wk |
| Chan et al[80], 2019   | Prospective trial                        | In CHB patients, switched to weekly PEG-IFN alfa-2a after seroconversion on entecavir, those with lower HBsAg titers, showed a greater sustained response (88% at HBsAg < 1500 IU/mL and 50% at HBsAg < 500 IU/mL) |
| Chen et al[82], 2020   | Meta-analysis                            | Confirmed the importance of longer treatment duration and addition of IFN for HBsAg lowering and highlighted the potential value of immune-based therapies |
| New direct antiviral agents |                                         |                                                                          |
| Ramanan et al[95], 2015 | Pre-clinical prospective study          | Use of ccc DNA endonucleases (CRISPR/Cas9) resulted in a reduction in both ccc DNA and other parameters of viral gene expression and replication in vitro |
| Yuen et al[96], 2019   | Phase I prospective trial                | Non-cirrhotic HBeAg-positive CHB patients, tolerated NVR 3-778 (a capsid assembly protein modulator), and showed reduced serum levels of HBV DNA and HBV RNA, to the greatest extent in combination with PEG-IFN |
| Yuen et al[97], 2020   | Phase I, randomized placebo-controlled trial | Demonstrated acceptable safety, pharmacokinetics, and antiviral effects on an investigational HBV core protein inhibitor ABI-H0731 |
| Zhao et al[98], 2019   | Phase I, randomized controlled trial     | Demonstrated acceptable safety and pharmacokinetics of GLS4 (a novel HBV capsid assembly inhibitor), with or without ritonavir (used to enhance plasma levels of GLS4) |
| Vandenbossche et al[99], 2019 | Phase I double-blind, randomized     | Demonstrated acceptable safety and pharmacokinetics of JNJ-56136379 (a

© Shah NJ et al. Recent advances in chronic hepatitis B
Shah NJ et al. Recent advances in chronic hepatitis B

| Reference | Year | Study Type | Description |
|-----------|------|------------|-------------|
| Han et al[103], 2019 | Phase I double-blind, randomized controlled trial | Demonstrated acceptable safety and pharmacokinetics of GS-9620 (a liver-targeted antisense oligonucleotide that inhibits the synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins) |
| Janssen et al[110], 2018 | Phase II prospective trial | Administration of a 12-wk course of GS-9620 (TLR7 agonist) was safe but did not significantly affect serum HBsAg levels. However, it did increase T-cell and NK-cell responses |
| Agarwal et al[111], 2018 | Randomized controlled prospective trial | Addition of Vesatolimod (TLR7 agonist) to Tenofovir in treatment naïve viremic Hepatitis B patients was found to be safe. This intervention led to dose dependent pharmacodynamic induction of IFNs, without significant improvement in HBsAg decline |
| Al Mahtab et al[114], 2018 | Open-label phase III trial | Treatment naïve CHB patients showed significantly better controlled HBV DNA, 24 wk post-treatment (P < 0.05) and a lower rate of progression to cirrhosis in the NASVAC group (therapeutic vaccine, containing 100 μg of each HBs and HBe antigens, administered in 2 cycles of 5 doses), versus Peg-IFN alfa 2b (weekly 180 μg) |
| Lai et al[115], 2018 | Randomized controlled prospective trial | In low-level HBsAg CHB patients, serial HBsAg-based vaccinations were safe, resulting in significant HBsAg decline. HLA gene expression and genotypes played a role in vaccine responsiveness |
| Boni et al[116], 2019 | Multicenter phase II prospective randomized controlled trial | Demonstrated improved HBV specific T cell responses, including IFN-γ, TNF-α, and IL-2, with a combined GS-4774 (yeast-based engineered vaccine) and tenofovir versus tenofovir alone |
| Wu et al[117], 2019 | Prospective controlled trial(The HBV Endeavor prospective trial) | HBV patients with confirmed viral suppression and HBsAg loss while on ETV, when switched to immunomodulators (IL-2) and therapeutic vaccines with IFN, showed HBsAg loss in 9.3%, 3.03%, and 3.7% in the IFN/vaccine/IL-2 group, IFN group, and the ETV group, respectively. Higher titer of CD16-NK cells and lower titers of regulatory T cells corresponded to higher response rates of HBsAg loss |
| Kalkeri et al[142], 2020 | Prospective trial | A repurposed compound SRI-32007 demonstrated anti-HBV activity via inhibition of HBV core promoter activity, and might be used in studying therapeutics to manage HBV |

### New immune based therapies

**Hepatitis B in pregnancy**

| Reference | Year | Study Type | Description |
|-----------|------|------------|-------------|
| Cressey et al[120], 2018 | Phase III randomized prospective trial | Demonstrated a geometric mean tenofovir AUC (0-24) to be 20% (19%-21%) lower during pregnancy than postpartum, in HBV patients with HIV, should not warrant a dose adjustment (to compensate for the modest reduction in HBV transmission) |
| Lin et al[121], 2018 | Randomized double-blind prospective trial | Initiation of TDF at 24th week of gestation and then 4 weeks after delivery reduced the MTCT from 13.5% (control group) to 0% cervical transmission, in pregnant HBsAg and HBeAg positive patients with high viral loads HBV DNA titer ≥ 2 × 10^6 IU/mL |
| Wang et al[122], 2019 | Prospective trial | Initiation of TDF at 24th week of gestation revealed a 0.7% MTCT in the ITT group, and 0% in the per protocol group, in pregnant HBsAg and HBeAg positive patients with high viral loads HBV DNA titer > 6 log_{10} IU/mL |
| Jourdain et al[123], 2018 | Multicenter, double-blind clinical trial | Initiation of TDF at 28th week of gestation till 2 mo postpartum mildly reduced the MTCT from 2% (control group) to 0% cervical transmission, in pregnant HBsAg and HBeAg positive patients with an ALT of < 60. The authors showed that addition of TDF only mildly reduced the MTCT to infants at age 6 mo |
| Wu et al[125], 2019 | Randomized control trial | Immune-tolerant CHB patients awaiting assisted reproduction showed greater viral clearance (90% vs 67.2%, P = 0.002 at week 12, and 96.6% compared to 85.2 % at week 48 respectively) when on a combination of TDF and telbivudine, compared to TDF alone. No difference was noted in the HBsAg seroconversion rates for the two groups (8.3% vs 3.3%, P = 0.233) |

### Hepatitis B reactivation
The incidence of HBV reactivation in patients on Ibrutinib was 9.5% (2/21 patients) [132, 2018]. In a recent study, 326 patients with prior HBV receiving Obinutuzumab or Rituximab for B-Cell Non-Hodgkin’s lymphoma (NHL) either received prophylactic NAs or underwent HBV DNA guided preemptive NA therapy. Multivariate regression analysis identified that seronegativity for anti-HBs and detectable HBV DNA levels at baseline (not the drug choice) were associated with increased risk of HBV reactivation [130, 2019]. While the reactivation rate was lower for patients receiving prophylactic antivirals, none of the patients in either group developed HBV-related hepatitis [130]. Results suggest that while prophylactic therapy can prevent reactivation and may be suitable for selected high-risk patients, HBV DNA-guided preemptive therapy can successfully prevent HBV hepatitis during anti-CD20 immunotherapy in B-cell NHL. Liu et al. [138, 2020] conducted an RCT on lymphoma patients with SARS-CoV-2 infection had a 15% risk of HBV reactivation ([138, 2020]. The role of baseline anti-HBs testing in this cohort is still not clear. Additionally, the data on hepatitis B reactivation during treatment with some of the newer immunotherapy agents such as obinutuzumab and Ibrutinib is sparse.

**Anticancer therapy**

Previous studies showed that HBV reactivation from anticancer therapies occurred in 41% to 53% of HBsAg-positive, anti-HBc-positive patients, and 8% to 18% of HBsAg-negative, anti-HBc-positive patients [126, 127]. Those receiving B cell depleting therapies such as Rituximab are considered to be at a higher risk of reactivation [128, 129]. The AASLD recommends screening patients requiring chemotherapy with both HBsAg and anti-HBc and prophylaxis with NAs before treatment initiation with B cell depleting therapies such as rituximab [10]. The role of baseline anti-HBs testing in this cohort is still not clear. Additionally, the data on hepatitis B reactivation during treatment with some of the newer immunotherapy agents such as obinutuzumab and Ibrutinib is sparse.

In a recent study, 326 patients with prior HBV receiving Obinutuzumab or Rituximab for B-Cell Non-Hodgkin’s lymphoma (NHL) either received prophylactic NAs or underwent HBV DNA guided preemptive NA therapy. Multivariate regression analysis identified that seronegativity for anti-HBs and detectable HBV DNA levels at baseline (not the drug choice) were associated with increased risk of HBV reactivation [130]. While the reactivation rate was lower for patients receiving prophylactic antivirals, none of the patients in either group developed HBV-related hepatitis [130]. Results suggest that while prophylactic therapy can prevent reactivation and may be suitable for selected high-risk patients, HBV DNA-guided preemptive therapy can successfully prevent HBV hepatitis during anti-CD20 immunotherapy in B-cell NHL. Liu et al. [138, 2020] conducted an RCT on lymphoma patients with SARS-CoV-2 infection had a 15% risk of HBV reactivation ([138, 2020]. The role of baseline anti-HBs testing in this cohort is still not clear. Additionally, the data on hepatitis B reactivation during treatment with some of the newer immunotherapy agents such as obinutuzumab and Ibrutinib is sparse.

In a recent study, 326 patients with prior HBV receiving Obinutuzumab or Rituximab for B-Cell Non-Hodgkin’s lymphoma (NHL) either received prophylactic NAs or underwent HBV DNA guided preemptive NA therapy. Multivariate regression analysis identified that seronegativity for anti-HBs and detectable HBV DNA levels at baseline (not the drug choice) were associated with increased risk of HBV reactivation [130]. While the reactivation rate was lower for patients receiving prophylactic antivirals, none of the patients in either group developed HBV-related hepatitis [130]. Results suggest that while prophylactic therapy can prevent reactivation and may be suitable for selected high-risk patients, HBV DNA-guided preemptive therapy can successfully prevent HBV hepatitis during anti-CD20 immunotherapy in B-cell NHL. Liu et al. [138, 2020] conducted an RCT on lymphoma patients with SARS-CoV-2 infection had a 15% risk of HBV reactivation ([138, 2020]. The role of baseline anti-HBs testing in this cohort is still not clear. Additionally, the data on hepatitis B reactivation during treatment with some of the newer immunotherapy agents such as obinutuzumab and Ibrutinib is sparse.

In a recent study, 326 patients with prior HBV receiving Obinutuzumab or Rituximab for B-Cell Non-Hodgkin’s lymphoma (NHL) either received prophylactic NAs or underwent HBV DNA guided preemptive NA therapy. Multivariate regression analysis identified that seronegativity for anti-HBs and detectable HBV DNA levels at baseline (not the drug choice) were associated with increased risk of HBV reactivation [130]. While the reactivation rate was lower for patients receiving prophylactic antivirals, none of the patients in either group developed HBV-related hepatitis [130]. Results suggest that while prophylactic therapy can prevent reactivation and may be suitable for selected high-risk patients, HBV DNA-guided preemptive therapy can successfully prevent HBV hepatitis during anti-CD20 immunotherapy in B-cell NHL. Liu et al. [138, 2020] conducted an RCT on lymphoma patients with SARS-CoV-2 infection had a 15% risk of HBV reactivation ([138, 2020]. The role of baseline anti-HBs testing in this cohort is still not clear. Additionally, the data on hepatitis B reactivation during treatment with some of the newer immunotherapy agents such as obinutuzumab and Ibrutinib is sparse.

Huang et al. [127, 2013] conducted a randomized double-blind prospective trial of prophylaxis with ETV significantly reduced HBV reverse seroconversion when compared with placebo in resolved hepatitis B patients receiving Rituximab for lymphoma (4.3% vs. 25.9% at 18 mo; P = 0.019).

Kusumoto et al. [130, 2019] conducted a prospective trial of resolved HBV patients with NHL, who received obinutuzumab or rituximab, and followed for HBV reactivation, revealed a strong correlation (P = 0.0033) of HBV reactivation with detectable baseline HBV DNA. Also, prophylactic NA reduced risk of HBV reactivation (P = 0.0023). A meta-analysis by Zhang et al. [136, 2019] showed that HBV DNA negative patients with HCC who underwent TACE were at significant lower risk of HBV reactivation compared to HBV DNA positive patients (5.9% vs. 23.4%; P = 0.005).

Hammond et al. [132, 2018] conducted a retrospective study of the incidence of HBV reactivation, in patients on Ibrutinib, was 9.5% (2 out of 21 patients with known past HBV infection).

Wang et al. [135, 2018] conducted a prospective trial of HBV DNA negative patients with HCC who underwent TACE were at significant lower risk of HBV reactivation compared to HBV DNA positive patients (5.9% vs. 23.4%; P = 0.005).

Zhang et al. [136, 2019] conducted a meta-analysis of HBV DNA negative patients with HCC who underwent TACE were at significant lower risk of HBV reactivation compared to HBV DNA positive patients (5.9% vs. 23.4%; P = 0.005).

Jun et al. [137, 2018] conducted a multi-center retrospective study of 12.7% of HBV DNA negative patients with HCC who underwent RT had HBV reactivation. Use of prophylactic anti-viral therapy significantly reduced the risk of HBV reactivation (P < 0.001), when compared to the control group. Combined RT and TACE had significant risk for HBV reactivation (P = 0.008).

Liu et al. [138, 2020] conducted a retrospective study of CHB patients with SARS-CoV-2 infection had a 15% risk of HBV reactivation.

CHB: Chronic hepatitis B; HBV: Hepatitis B virus; HBeAg: Hepatitis B e-antigen; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir; NA: Nucleos(t)ide analog; TLR7: Toll like receptor 7; YIC: Hepatitis B surface antigen-hepatitis B immunoglobulin immune complex; AST: Aspartate aminotransferase; ALT: Alanine aminotransaminase; PEG-IFN: Pegylated interferon; cccDNA: Covalently closed circular DNA; CRSIP: Clustered regularly interspaced short palindromic repeats; Cas9: CRISPR associated protein 9; NK: Natural killer; IFN: Interferon; TNF: Tumor necrosis factor; IL-2: Interleukin 2; CD: Cluster of differentiation; HBIG: Hepatitis B immune globulin; AUC: Area under the ROC curve; ROC: Receiver operating characteristic; CI: Confidence interval; ITT: Intention to treat; MTCT: Maternal to child transmission; NHL: Non-Hodgkin’s lymphoma; TACE: Trans-arterial chemoembolization; RT: Radiotherapy; HCC: Hepatocellular carcinoma; GGT: Gamma-glutamyl transferase; ISGs: Interferon stimulated gene transcripts; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

0.002 at week 12, and 96.6% compared to 85.2% at week 48 respectively) in patients on a combination of TDF and telbivudine, compared to TDF alone. However, there was no difference in the HBsAg seroconversion rates for the two groups (8.3% vs 3.3% P = 0.233) [125] (Table 3).
patients on chemotherapy with past HBV infection (HBsAg negative, Anti HBV core total antibody positive, and negative HBV DNA), and the study concluded that the prophylactic use of ETV was not a cost-effective strategy, especially for those with a positive anti-HBs. The HBV reactivation was 3.2% compared to 0% \((P = 0.246)\), in controls vs those of prophylactic ETV\(^{133}\). In a recent retrospective review, the authors identified two patients suffering from chronic lymphocytic leukemia who experienced hepatitis B reactivation after treatment with Ibrutinib. The incidence of hepatitis B reactivation, in patients on Ibrutinib, at the Dana-Farber/Harvard Cancer Institute was 9.5% (2 out of the 21 patients with known past HBV infection)\(^{132}\).

These studies highlight the risk of hepatitis B reactivation with novel agents such as obinutuzumab and ibrutinib, the utility of baseline anti-HBs testing for risk stratification, and argue in favor of close surveillance with preemptive treatment being a safe and cost-effective strategy in these patients.

CHB patients receiving transarterial chemoembolization (TACE) for HCC are at a modestly increased risk for hepatitis B reactivation\(^{133,134}\). There is a lack of systemic data assessing antivirals' role in this subgroup of patients, and the most recent AASLD guidelines do not address this issue directly as such data from high-quality prospective trials and meta-analysis are needed to advance our knowledge of this field. In a recent prospective trial including 98 CHB patients with HCC requiring TACE, prophylactic antivirals were associated with a significant reduction in the incidence of hepatitis B reactivation (5.9% vs 23.4% \(P < 0.05\))\(^{135}\). Zhang et al\(^{136}\) recently performed a meta-analysis to investigate the reactivation of HBV following TACE in primary HCC patients (HBV-DNA negative) and evaluate TACE's effects combined with antiviral therapy. TACE significantly increased the risk of HBV reactivation (OR: 3.70; 95%CI: 1.45-9.42; \(P < 0.01\)) and subsequent hepatitis (OR: 4.30; 95%CI: 2.28-8.13; \(P < 0.01\)) in HCC patients. Preventive antiviral therapy reduced the rate of HBV reactivation (OR: 0.08; 95%CI: 0.02-0.32; \(P < 0.01\)) and hepatitis (OR: 0.22; 95%CI: 0.06-0.80; \(P = 0.02\)) in those undergoing TACE\(^{136}\). A recent multicenter retrospective study evaluated 133 patients receiving radiotherapy +/- TACE for the treatment of HCC, and the effect of antiviral therapy on HBV reactivation in quiescent HBsAg positive patients after radiotherapy for HCC was found to be 33.3% in the non-antiviral group, compared to 7.5% in the antiviral group, with a \(P < 0.001\)\(^{137}\).

**CORONAVIRUS DISEASE 2019**

Another interesting HBV reactivation phenomenon was described by Liu et al\(^{138}\) in patients who are not necessarily immune-compromised but just infected with coronavirus disease 2019 (COVID-19). Liver dysfunction is apparent in COVID-19 patients with/without chronic HBV. COVID-19 patients co-infected with chronic HBV were found to be at risk of hepatitis B reactivation, making it necessary to monitor the liver function of COVID-19 patients concurrently with HBV-DNA levels during the whole disease course\(^{138}\).

**FUTURE DIRECTIONS**

In November 2019, the NIH hepatitis B cure strategic plan working group released a visionary statement to end the hepatitis B endemic by improved screening, strategies for vaccinations, developing better hepatitis B treatment, and follow-up care. This guidance serves as a foundation for future concerted international efforts and would further help develop novel biomarkers to diagnose disease progression, in addition to novel therapeutics\(^{139}\). Due to the need for lifelong treatment, adverse effects, poor tolerability, and persistent risk of complications, including HCC, render the current treatments dissatisfactory.

The discovery of NTCP as an HBV receptor on human hepatocytes was the first of many critical discoveries that have revolutionized HBV research. Over the past decade, the discovery has translated into a significantly improved understanding of HBV pathogenesis and led to the development of novel animal models, cell lines, biomarkers, and therapeutic agents. Our armamentarium of potential HBV drugs has undergone a rapid expansion. Direct antivirals currently being studied include HBV entry inhibitors, capsid assembly modulators, cccDNA destabilizers and endonucleases, HBX inhibitors, Inhibitors of gene expression, HBsAg release inhibitors\(^{13}\). These agents are likely going to complement existing treatments rather than replacing them. Given the safety profile of NAs, novel agents will likely be compared and
Shah NJ et al. Recent advances in chronic hepatitis B

combined with NAIs in upcoming trials. The initial cure for HBV will most likely require a combination of agents that modulate viral and host factors at various levels. Given the efficacy of T cells for viral control in acute hepatitis, they have been studied extensively. Novel agents act either through innate and intrinsic cell responses (Toll-like receptor agonists, RIG-I) or by targeting adaptive immune responses (checkpoint inhibitors, therapeutic vaccines, genetically engineered T cells/antibodies).

Loss of T cell response to HBV or T cell exhaustion is multifactorial in nature and a major hurdle to the development of immunomodulatory therapeutic agents. These concepts have been incorporated into therapeutic strategies that involve potent adjuvants, monoclonal antibodies, or pattern recognition receptor agonists that alter the liver environment. On the other hand, our understanding of HBV-specific B cells is limited to antibody production, and further studies are required to understand better their cytokine profiles and their role as antigen-presenting cells.[106]

Another major limitation to preclinical testing of novel agents is the lack of optimal animal models. Because of the strict species specificity of HBV infection, animal models for studying the host response to the virus and disease pathogenesis have been limited and suboptimal.[140] Chimpanzees are the only nonhuman immunocompetent animals that are naturally susceptible to HBV infection. However, given the discontinuation of chimpanzees’ use due to bioethical considerations, the only other option is Tupaia (a tree shrew), woodchuck, or mice, all of which have significant drawbacks.[141] Future efforts to develop antiviral agents against viral genome reservoir or cccDNA or promote the patient’s antiviral response must include the development of infection models that are durable, stable, and more reflective of the natural HBV life cycle within the human host.

To this end, drug repurposing may offer reduced effort, time, and cost related to new drugs’ the testing and marketing of new drugs. Drug repurposing involves the investigation of existing drugs with demonstrated safety profiles for new therapeutic purposes. Thousands of compounds can be screened for the desired effect using high throughput screening. A recent study demonstrated anti-HBV activity of a repurposed compound SRI-32007 through inhibition of HBV core promoter activity.[142] Drug repurposing may allow for more systematic and substantially less expensive methods to discover new treatments for diseases compared to traditional drug development.

To promote and facilitate the planning and execution of new trials in the field of CHB with the ambition of developing a ‘cure’, the European Association for the Study of the Liver and the AASLD jointly organized an HBV Treatment Endpoint Conference.[13] The conference provided a strategy for conducting efficient phase II/III trials while maintaining excellent safety profiles. It was agreed upon that the primary endpoint of phase III trials should be HBsAg loss and undetectable HBV DNA 6 mo after completion of treatment. HBsAg loss in ≥ 30% of patients after 1 year of therapy is the desired rate of response in these phase III trials.

A comprehensive collaboration within the scientific community is required to standardize definitions, methods, and endpoints to achieve a complete understanding of viral biology and develop novel therapies in a time and cost-effective manner. That will be, however, just the beginning of the global battle against HBV. The WHO has identified significant barriers that hinder efforts to prevent and treat CHB in the most vulnerable populations. Structural barriers include inadequate leadership, commitment, coverage of prevention programs, data, and a lack of public health approach to hepatitis. Personal barriers include lack of education/insight, widespread stigma, and discrimination, lack of affordability, and healthcare access. With these challenges in mind, the WHO has developed a core strategy to eliminate viral hepatitis as a public health threat by 2030, to reduce new infections by 90% and mortality by 65%.[34]

The cornerstone of this global strategy is going to be a pragmatic and efficient vaccination program. Hepatitis B vaccine is one of the most effective vaccines, with seroconversion rates above 90% when administered properly. Additional studies are needed to identify the host genetic factors and immune mechanisms that lead to a non-response in immunocompetent patients. The vaccination response of the immunocompromised host needs to be better studied, and practical strategies including immune priming need to be developed to achieve higher seroconversion rates. Vaccines biology can potentially help define, at baseline, predictive signatures for subjects generating protective responses following HBV vaccination leading to more personalized vaccination.[143] These findings need further testing to validate the concept of baseline predictors and the feasibility and utility of targeted modulation of the immune baseline before vaccinations.[143] Elimination of HBV infection as a public health threat requires a reduction in the prevalence of HBsAg to below 0.1% in children five years of age. It can be achieved through universal immunization of newborns against hepatitis B and other interventions to prevent mother-to-child transmission of HBV.
Significant challenges include low availability of HBIG due to the lack of resources required for storage and transportation and prohibitive cost. Despite the efficacy of vaccination in reducing MTCT, the birth dose vaccine coverage, especially in the African region, remains low[124]. Lack of infrastructure leads to reduced ability to test for HBV DNA and limits antiviral availability in high-risk populations. The immunocompromised patients also remain at a high risk of reactivation despite an initial vaccination response and positive antibody titers. Researchers have relied on Genome-wide association studies genome-wide association studies (GWAS) to identify the risk loci that predispose to the persistence of HBV infection, non-response to hepatitis B vaccine, and liver disease progression in chronic HBV infections[144]. Additional GWAS and fine-mapping studies, implemented with more refined case-control designs, larger samples, and in other ethnic populations, would further improve our understanding of HBV pathophysiology[144].

CONCLUSION
The breakthrough in our understanding of the HBV life cycle has resulted in a plethora of novel direct acting antivirals and immune based therapies being investigated. In the foreseeable future however, novel agents are likely to complement PEG-IFN and NAs than replace them. Recent studies utilizing combination regimens (PEG-IFN plus NA) and a longer duration of treatments with PEG-IFN have shown improved outcomes. Additionally, trials assessing alternate vaccination regimens for primary non-responders, and perinatal NAs for prevention of MTCT in high-risk individuals have shown promise and may alter future guidelines. Studies on novel biomarkers are fraught with technical difficulties, lack of standardization, and small sample size. Despite remarkable efficacy, the hepatitis B vaccine remains poorly utilized in many regions of the world due to a lack of infrastructure and implementation. Data from high-risk populations, most vulnerable to the devastating effects of hepatitis B infection and reactivation remain sparse. Utilization of systems approach, optimization of experimental models, identification and validation of next-generation biomarkers, and precise modulation of the human immune response will be critical for future innovation. Last but not the least, pragmatic management of MTCT and population health-related challenges must be prioritized to produce real-world results.

REFERENCES
1. Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 2013; 57: 908-916 [PMID: 22987324 DOI: 10.1002/hep.26079]
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
3. Yuen MF, Chen DS, Dasheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers 2018; 4: 18035 [PMID: 29877316 DOI: 10.1038/s41573-018-0035-5]
4. World Health Organization. Hepatitis B. [cited 21 December 2020]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
5. Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 2019; 18: 827-844 [PMID: 31455905 DOI: 10.1038/s41555-019-0037-0]
6. Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HL, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc 2019; 118: 7-38 [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008]
7. European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]
8. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafari W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]
9. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association
for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology* 2016; 63: 261-283 [PMID: 26566064 DOI: 10.1002/hep.28156]

10 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018; 67: 1560-1599 [PMID: 29405329 DOI: 10.1002/hep.29800]

11 Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. *Semin Liver Dis* 1991; 11: 73-83 [PMID: 1904558 DOI: 10.1055/s-2005-840426]

12 US Preventive Services Task Force. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr, Kubik M, Ogedegbe G, Owens DK, Phibert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *JAMA* 2020; 324: 2415-2422 [PMID: 33320330 DOI: 10.1001/jama.2020.22980]

13 Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. *J Hepatol* 2020; 72: 539-557 [PMID: 31730785 DOI: 10.1016/j.jhep.2019.11.003]

14 Zhang P, Du HB, Tong GD, Li XK, Sun XH, Chi XL, Xing YF, Zhou ZH, Li Q, Chen B, Wang H, Wang L, Jin H, Mao DW, Wang XB, Wu QK, Li FP, Hu XY, Lu BJ, Yang ZY, Zhang MX, Shi WB, He Q, Li Y, Jiang KP, Xue JD, Li XD, Jiang JM, Lu W, Tian GJ, Hu ZB, Guo JC, Li CZ, Deng X, Luo XL, Li FY, Zhang XW, Zheng YJ, Zhao G, Wang LC, Wu JH, Guo H, Mi YQ, Gong ZJ, Wang CB, Jiang F, Guo P, Yang XZ, Shi WQ, Yang HZ, Zhou Y, Sun NN, Jiao YT, Gao YQ, Zhou DQ, Ye YA. Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: A multicentre perspective in China. *J Viral Hepat* 2018; 25: 1017-1025 [PMID: 29624802 DOI: 10.1111/jvhe.12903]

15 Walsh R, Hammond R, Yuen L, Dearain J, O’Donnell T, Leary T, Cloherty G, Gaggar A, Kitirosis K, Subramanian M, Wong D, Locarnini S. Predicting HBsAg clearance: A biomarker for functional cure. *Liver Int* 2019; 39: 2066-2076 [PMID: 31379058 DOI: 10.1111/liv.14207]

16 Mak LY, Seto WK, Fung J, Yuen MF. New Markers for Chronic Hepatitis B. *Gut Liver* 2019; 13: 589-595 [PMID: 30919601 DOI: 10.5009/gnl18425]

17 DuranTed D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. *J Hepatol* 2016; 64: S117-S131 [PMID: 27084032 DOI: 10.1016/j.jhep.2016.02.016]

18 Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, Maki N. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol* 2002; 40: 439-445 [PMID: 11825954 DOI: 10.1128/JCM.40.2.439-445.2002]

19 Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K, Ohno S, Maki N. Hepatitis B virus DNA-negative naive particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. *J Biol Chem* 2005; 280: 21713-21719 [PMID: 15814524 DOI: 10.1074/jbc.M501264200]

20 Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, Yuen MF. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. *Clin Microbiol Infect* 2014; 20: 1173-1180 [PMID: 24975365 DOI: 10.1111/cmi.12329]

21 Rokuhara A, Sun X, Tanaka E, Kimura T, Matsumoto A, Yao D, Yin L, Wang N, Maki N, Kiyosawa K, Nakanuma N, Nakanuma T, Yagi S, Maki N. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. *J Viral Hepat* 2003; 10: 324-330 [PMID: 12823601 DOI: 10.1046/j.1365-2893.2003.00437.x]

22 Seto WK, King SA, Cheung KS, Chong CK, Huang FY, Fung J, Lai CL, Yuen MF. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. *Am J Gastroenterol* 2016; 111: 1788-1795 [PMID: 27644733 DOI: 10.1038/ajg.2016.436]

23 Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Sul SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. *Clin Mol Hepatol* 2016; 22: 382-389 [PMID: 27729633 DOI: 10.3350/cmh.2016.0047]
Shah NJ et al. Recent advances in chronic hepatitis B

28 Jung KS, Park JY, Chon YE, Kim HS, Kang W, Kim BK, Kim SU, Kim do Y, Han KH, Ahn SH. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016; 51: 830-839 [PMID: 26867058 DOI: 10.1007/s00535-015-1153-1]

29 Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, Yuan Q, Li PC, Huang Q, Colombo R, Jia J, Hou J, McCrae MA, Gao Z, Ren H, Xia N, Zhai H, Lu F. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016; 65: 700-710 [PMID: 27245431 DOI: 10.1016/j.jhep.2016.05.029]

30 Butler EK, Gorsch J, McNamara A, Luk KC, Holzmayer V, de Medina M, Schiff E, Kuhns M, Cloherty GA. Hepatitis B Virus Serum DNA and RNA Levels in Nucleos(t)ide Analogue-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology 2018; 68: 2106-2117 [PMID: 29734472 DOI: 10.1002/hep.30082]

31 Wang J, Yu Y, Li G, Shen C, Li J, Chen S, Zhang X, Zhu M, Zheng J, Song Z, Wu J, Shao L, Meng Z, Wang X, Huang Y, Zhang J, Qiu C, Zhang W. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 2018; 25: 1038-1047 [PMID: 29633430 DOI: 10.1111/jvh.12908]

32 Gao Y, Li Y, Meng Q, Zhang Z, Zhao P, Shang Q, Su M, Li T, Liu X, Zhai H. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment? J Clin Microbiol 2017; 55: 2972-2982 [PMID: 28747369 DOI: 10.1128/JCM.00760-17]

33 Tsuge M, Murakami E, Inamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. Serum HBV RNA and HBcAg, Chayama useful markers for the safe discontinuation of nucleoside analogue treatments in chronic hepatitis B patients. J Gastroenterol 2013; 48: 1188-1204 [PMID: 23397114 DOI: 10.1007/s00535-012-0737-2]

34 Chang XJ, Sun C, Chen Y, Li XD, Yu ZL, Dong Z, Bai WL, Wang XD, Li QZ, Chen D, Wu J, Liao H, Jiang QY, Sun LJ, Li YY, Zhang CH, Xu DP, Chen YP, Li Q, Yang YP. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25: 4764-4778 [PMID: 31528100 DOI: 10.3748/wjg.v25.i32.4764]

35 Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, Li Q, Liu L, Huang B, Lu F, Xu D. Monitoring of serum HBV RNA, HBcAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther 2019; 24: 105-115 [PMID: 30511941 DOI: 10.3851/IMP2820]

36 Gao M, Feng C, Ying R, Nie Y, Deng X, Zhu Y, Tang X, Guan Y, Hu F, Li F. A novel one-step quantitative reverse transcription PCR assay for selective amplification of hepatitis B virus pregenomic RNA from a mixture of HBV DNA and RNA in serum. Arch Virol 2019; 164: 2683-2690 [PMID: 31428915 DOI: 10.1007/s00705-019-04372-0]

37 Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, von Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. J Hepatol 2019; 70: 314-320 [PMID: 33222190 DOI: 10.10111/apt.16172]

38 Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017; 167: 794-804 [PMID: 29159414 DOI: 10.7326/M11-1106]

39 Bhat M, Ghali P, Deschenes M, Wong P. Hepatitis B and the infected health care worker: public safety at what cost? Can J Gastroenterol 2012; 26: 257-260 [PMID: 22590698 DOI: 10.1155/2012/348240]

40 Middleton AB, Baker CJ, Kozinetz CA, Kamili S, Nguyen C, Hu DJ, Spradling PR. Duration of protection after infant hepatitis B vaccination series. Pediatrics 2014; 133: e1500-e1507 [PMID: 24843060 DOI: 10.1542/peds.2013-2940]

41 FDA. Product approval information: package insert. Heplisav-B. Silver Spring, MD: US Department of Health and Human Services. FDA Med Bull 2018. [cited 21 December 2020]. Available from: https://www.fda.gov/

42 Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR Morb Mortal Wkly Rep 2018; 67: 455-458 [PMID: 29672472 DOI: 10.15585/mmwr.mm6715a5]

43 Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011; 53: 68-75 [PMID: 21653306 DOI: 10.1093/cid/cir270]

44 Hepatitis B Foundation. Vaccine Non-Responders. [cited 25 December 2020]. Available from: https://www.hepb.org/prevention-and-diagnosis/vaccination/vaccine-non-responders/

45 Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006; 78: 169-177 [PMID: 16372285 DOI: 10.1002/jmv.20524]

46 Hamborsky J, Kroger A, Wolfe C. Epidemiology and Prevention of Vaccine-preventable Diseases. Centers for Disease Control and Prevention; 2015. [cited 25 December 2020]. Available from: https://play.google.com/store/books/details/id=UCf9rgFAA/AAJ

47 Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of Hepatitis
Chen L, Xie Q, Sung JJ, Messinger D, Wat C, Bakalos G, Liaw YF. Responses are durable for up to
10.1038/s41409-020-0833-5
Bone Marrow Transplant of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation.
Inoue K, Kusumoto S, Hashino S, Saito H, Kanto T, Sakamaki H, Mizokami M. A prospective trial
Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T,
SA, Perales MA. Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe
Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt
Palazzo M
Hum Vaccin Immunother
DOI:
10.1371/journal.pone.0204477
PLOS One 2018; 13:
506
for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;
50: 1-43 [PMID: 11349873]
57 Grzegorzecka AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-
dialyzed patients. Hepat Mon 2012; 12: e7359 [PMID: 23326280 DOI: 10.5812/hepatmon.7359]
58 FitzSimons D, Hendricks G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed
schedule enough to control HBV lifelong? Vaccine 2013; 31: 584-590 [PMID: 23142301 DOI:
10.1016/j.vaccine.2012.10.101]
59 Van Damme P, Dionne M, Leroux-Roels G, Van Der Meeren O, Di Paolo E, Salaun B, Surya Kiran P,
Felschweiller N. Persistence of HBsAg-specific antibodies and immune memory two to three
days after hepatitis B vaccination in adults. J Viral Hepat 2019; 26: 1066-1075 [PMID:
31087382 DOI: 10.1111/jvhe.13125]
60 Hovi L, Valle M, Siimes MA, Jalanko H, Saarinen UM. Impaired response to hepatitis B vaccine in
children receiving anticancer chemotherapy. Pediatr Infect Dis J 1995; 14: 931-935 [PMID:
8584357 DOI: 10.1097/00006454-199511000-00002]
61 Zuin G, Principi N, Tornaghi R, Paccagnini S, Re M, Massironi E, Ragni MC. Impaired response to
hepatitis B vaccine in HIV infected children. Vaccine 1992; 10: 857-860 [PMID: 1455911 DOI:
10.1016/0264-410X(92)90050-4]
62 Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S,
Sung L, Keyserling H, Kang I. Infectious Diseases Society of America. 2013 IDSA clinical practice
guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: e44-100
[PMID: 24311479 DOI: 10.1093/cid/cet684]
63 Chawansuntaki K, Chaiklang K, Chaiwarith R, Praparattanapan J, Supparatpinyo K, Wipasa J.
Hepatitis B Vaccination Induced TUNF- and IL-2-Producing T Cell Responses in HIV-
Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen. J
Immunol Res 2018; 2018: 850862 [PMID: 29868290 DOI: 11.1155/2018/850862]
64 Palazzo M, Shah GL, Copelan O, Seier K, Devin SM, Maloy M, Kenny S, Hassoun H, Korde NS,
Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Hiralt SA, Perales MA. Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biol Blood Marrow Transplant 2018; 24: 871-876 [PMID: 29288818 DOI: 10.1016/j.bbmt.2017.12.795]
65 Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kikihana K, Doki N, Ohashi K, Bae SK,
Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T,
Inoue K, Kusumoto S, Hashino S, Saito H, Kanto T, Sakamaki H, Mizokami M. A prospective trial of
vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transplant 2020; 55: 1388-1398 [PMID: 32071416 DOI:
10.1038/s41409-020-0833-5]
66 Karimkhanlouyi S, Ghorbian S. Nucleic acid vaccines for hepatitis B and C virus. Infect Genet Evol
2019; 75: 103968 [PMID: 31325699 DOI: 10.1016/j.meegid.2019.103968]
67 Chuang WL, Jia J, Chan HLY, Han KH, Tanwandeet T, Tan D, Chen X, Gane E, Piratvisuth T,
Chen L, Xie Q, Sung JJ, Messinger D, Wat C, Bakalos G, Liaw YF. Responses are durable for up to
5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. *Aliment Pharmacol Ther* 2018; 47: 1306-1316 [PMID: 29520872 DOI: 10.1111/apt.14595]

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssens HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trihã H, Flaherty JF, Gaggero A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-320-0110; GS-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. *J Hepatol* 2018; 68: 672-681 [PMID: 29756595 DOI: 10.1016/j.jhep.2017.11.039]

Yim HJ, Kim JH, Suh SJ, Jung YK, Kim JH, Seo YS, Yeon JE, Kim CW, Kwon SY, Park SH, Lee MS, Um SH, Byun KS. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. *J Viral Hepat* 2018; 25: 1321-1330 [PMID: 29772084 DOI: 10.1111/jvh.12934]

Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J, Woo HY, Hwang JS, Chung WJ, Lee CH, Kim BS, Suh JI, Tak WY, Jang BK. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. *PLoS One* 2018; 13: e0190581 [PMID: 29329305 DOI: 10.1371/journal.pone.0190581]

Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggero A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. *Liver Int* 2019; 39: 1868-1875 [PMID: 31136052 DOI: 10.1111/liv.14155]

Cai D, Pan C, Yu W, Dang S, Li J, Wu S, Jiang N, Wang M, Zhang Z, Lin F, Xin S, Yang Y, Shen B, Ren H. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBsAg-positive patients with chronic hepatitis B: A large, multicentre, randomised controlled trials. *Medicine (Baltimore)* 2019; 98: e13983 [PMID: 30608440 DOI: 10.1097/MD.0000000000013983]

Liang X, Xie Q, Tan D, Ning Q, Niu J, Bai X, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen Z, Ma H, Chen Y, Fan R, Sun J, Jia J, Hou J. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study. *J Viral Hepat* 2018; 25: 296-305 [PMID: 29080299 DOI: 10.1111/jvh.12814]

Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. *J Hepatol* 2005; 42: 302-308 [PMID: 15710212 DOI: 10.1016/j.jhep.2004.12.015]

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld J, Hansen BE, Janssens HLA. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). *Gut* 2019; 68: 2206-2213 [PMID: 31462554 DOI: 10.1136/gutjnl-2019-318981]

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssens HLA, Op den Brouw M, Jump B, Gaggero A, Flaherty J, Buti M. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. *Lancet Gastroenterol Hepatol* 2019; 4: 296-304 [PMID: 30795938 DOI: 10.1016/S2468-1253(19)30012-5]

Wong VW, Hui AJ, Wong GL, Chan RS, Chim AM, Lo AO, Chan HL. Four-year Outcomes After Cessation of Tenofovir in Immune-Tolerant Chronic Hepatitis B Patients. *J Clin Gastroenterol* 2018; 52: 347-352 [PMID: 28723855 DOI: 10.1097/MCG.0000000000000852]

Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssens HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. *Aliment Pharmacol Ther* 2019; 49: 448-456 [PMID: 30698258 DOI: 10.1111/apt.15098]

Lam perpetico P, Brunetto MR, Craxi A, Gaeta GB, Rizzetto M, Rozzi A, Colombo M; HERMES Study Group. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B e’ antigen-negative chronic hepatitis B genotype D. *J Viral Hepat* 2019; 26: 118-125 [PMID: 30187599 DOI: 10.1111/jvh.12999]

Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, Loo CK, Chin AML, Tse CH, Wong VWS. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. *J Viral Hepat* 2019; 26: 126-135 [PMID: 30187604 DOI: 10.1111/jvh.13000]

Chan HLY, Messinger D, Papathedoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lamperchio P. A baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients with chronic hepatitis B. *Aliment Pharmacol Ther* 2018; 48: S47-555 [PMID: 29956827 DOI: 10.1111/apt.14862]

Chen Y, Li JH, Chen R, Li G, Ji J. Dynamics of HBV surface antigen related end points in chronic hepatitis B with a systematic review and meta-analysis. *Antivir Ther* 2020; 25: 203-215 [PMID: 32609658 DOI: 10.3851/IMP3366]

Testin B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. *Liver Int* 2017; 37 Suppl 1: 33-39 [PMID: 28052622 DOI: 10.1111/liv.13307]

Tsukuda S, Wataishi K. Hepatitis B virus biology and life cycle. *Antiviral Res* 2020; 182: 104925 [PMID: 32866519 DOI: 10.1016/j.antiviral.2020.104925]

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Xui J, Li W. Sodium taurocholate cotransporting
polypeptide is a functional receptor for human hepatitis B and D virus. *Elife* 2012; 1: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049]

86 **Nkongolo S**, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. *J Hepatol* 2014; 60: 723-731 [PMID: 24293872 DOI: 10.1016/j.jhep.2013.11.022]

87 **Bogomolov P**, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wademenyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Treatment of chronic hepatitis D with the entry inhibitor mycoclude X: First results of a phase Ib/IIa study. *J Hepatol* 2016; 65: 490-498 [PMID: 27132170 DOI: 10.1016/j.jhep.2016.04.016]

88 **Iwamoto M**, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koivai O, Kusuahara H, Wakita T. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. *Biochim Biophys Acta Res Commun* 2014; 443: 808-813 [PMID: 24342612 DOI: 10.1016/j.bbr.2013.12.052]

89 **Ni Y**, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fältth M, Stindt J, Königner C, Nossal M, Kubritz R, Sültermann H, Urban S. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. *Gastroenterology* 2014; 146: 1070-1083 [PMID: 24361467 DOI: 10.1053/j.gastro.2013.12.024]

90 **Sun Y**, Qi Y, Peng B, Li W. NTCP-Reconstituted In Vitro HBV Infection System. *Methods Mol Biol* 2017; 1540: 1-14 [PMID: 27975303 DOI: 10.1007/978-1-4939-6700-1_1]

91 **Burwitz B**, Wettengel JM, Mlick-Häusl MA, Ringelhan M, Ko C, Festug MM, Hammond KB, Northrup M, Bimber BN, Jacob T, Reed JS, Norris R, Park B, Moller-Tank S, Esser K, Greene JM, Wu HL, Abdulhaq SG, Webb G, Sutton WF, Klug A, Swanson T, Legasse AW, Vu TQ, Asokan A, Haigwood NL, Protzer U, Sacha JB. Hepatic expression of human sodium-taurocholate co-transportating polypeptide enables hepatitis B virus entry of macaques. *Nat Commun* 2017; 8: 2146 [PMID: 28237188 DOI: 10.1038/s41467-017-01953-y]

92 **Eiler C**, Heydmann L, Colpitts CS, Verrier ER, Schuster C, Baumert TF. The functional role of sodium taurocholate co-transporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. *Cell Mol Life Sci* 2018; 75: 3895-3905 [PMID: 30097692 DOI: 10.1007/s00018-018-2892-y]

93 **Xia Y**, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. *Antiviral Res* 2020; 180: 104824 [PMID: 32450266 DOI: 10.1016/j.antiviral.2020.104824]

94 **World Health Organization**. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis, 2016. [cited 25 December 2020]. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf

95 **Ramanan V**, Shlomai A, Cox DB, Schwartz RE, Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN. CRISPR-Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. *Sci Rep* 2015; 5: 10833 [PMID: 26035283 DOI: 10.1038/srep10833]

96 **Yuen MF**, Gane EJ, Kim DJ, Weillert F, Yuan Chan HL, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. *Gastroenterology* 2019; 156: 1392-1403. e7 [PMID: 30625297 DOI: 10.1053/j.gastro.2018.12.023]

97 **Yuen MF**, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Rudy E, Liaw S, Yan R, Huang Q, Colonnio R, Lopatin U. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. *Lancet Gastroenterol Hepatol* 2020; 5: 152-166 [PMID: 31711752 DOI: 10.1016/S2468-1253(19)30346-2]

98 **Zhao N**, Jia B, Zhao H, Xu J, Sheng X, Luo L, Huang Z, Wang X, Ren Q, Zhang Y, Zhao X, Cui Y. A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers. *Antimicrob Agents Chemother* 2019; 64: 31636065 DOI: 10.1128/AAC.01686-19

99 **Vandenbossche J**, Jessner W, van den Boer M, Biewenga J, Berke JM, Talloen W, De Zwart L, Jessner W, van den Boer M, Biewenga J, Berke JM, Talloen W, De Zwart L, SNeeS Y, Yogaratnam J. Pharmacokinetics, Safety and Tolerability of JNJ-56156379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects. *Adv Ther* 2019; 36: 2450-2462 [PMID: 31267367 DOI: 10.1007/s12225-019-01017-1]

100 **Decorsière A**, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, Livingston CM, Niu C, Keller R, Sültmann H, Urban S. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-dependent phase 1 trials. *Adv Ther* 2019; 36: 2450-2462 [PMID: 31267367 DOI: 10.1007/s12225-019-01017-1]

101 **Sekiba K**, Otsuka M, Ohno M, Yamagami M, Shishikawa T, Suzuki T, Ishihashi R, Seimiya T, Tanaka E, Koike K. Inhibition of HBV Transcription From cccDNA With Nitisoxanide by Targeting the HBs-DBB Interaction. *Cell Mol Gastroenterol Hepatol* 2019; 7: 297-312 [PMID: 30704981 DOI: 10.1016/j.cmg.2018.10.010]

102 **Billoud G**, Kruse RL, Carrillo M, Whitten-Bauer C, Gao D, Kim A, Chen L, McCaleb ML, Crosby JR, Hamatake R, Hong Z, Garaigorta U, Swayne E, Bissig KD, Wieland S. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. *J Hepatol* 2016; 64: 781-789 [PMID: 26658683 DOI: 10.1016/j.jhep.2015.11.032]

103 **Han K**, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J,
Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GS-K3389/404 in Healthy Subjects. Clin Pharmacol Drug Dev 2019; 8: 790-801 [PMID: 30861337 DOI: 10.1002/cpdd.670]

104 Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 2014; 146: 1193-1207 [PMID: 24412289 DOI: 10.1053/j.gastro.2013.12.036]

105 Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, Becht E, Hanso NK, Foster GR, Su TH, Tseng TC, Lim SG, Kao JH, Newell EW, Kennedy PT, Bertolletta A. Hepatitis B virus-specific T cells associate with viral control upon nucleos(ide)-analogue therapy discontinuation. J Clin Invest 2018; 128: 668-681 [PMID: 29309050 DOI: 10.1172/JCI92812]

106 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3 [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038]

107 Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, Nanji A, Yuen ST, Williams R, Naohumov NV. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-624 [PMID: 11874993 DOI: 10.1053/gast.2002.31887]

108 Gehring AJ, Procter U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology 2019; 156: 325-337 [PMID: 30367834 DOI: 10.1053/j.gastro.2018.10.032]

109 Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Pizzolotta V, Lau A, Gaggia A, Subramanian GM, Ferrari C. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)ide Analogues. Gastroenterology 2018; 154: 1764-1777. e7 [PMID: 29378197 DOI: 10.1053/j.gastro.2018.01.030]

110 Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggia A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol 2018; 68: 431-440 [PMID: 29104121 DOI: 10.1016/j.jhep.2017.10.027]

111 Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggia A, Buhsu A, Tian X, Catcraft AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat 2018; 25: 1331-1340 [PMID: 29851204 DOI: 10.1111/jvh.12942]

112 Han J, Gong GZ, Lei JH, Qin WJ, Qin RH, Wang XY, Gu JX, Ren SF, Wen YM. Response to immune complex vaccine in chronic hepatitis B patients is associated with lower baseline level of serum IgG galactosylation. Medicine (Baltimore) 2019; 98: e16208 [PMID: 31261570 DOI: 10.1097/MD.0000000000016208]

113 Lim SG, Ageaaioli J, De Souza NNA, Chan E. Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. J Viral Hepat 2019; 26: 803-817 [PMID: 30801899 DOI: 10.1111/jvh.13085]

114 Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, Yoshida O, Hiasa Y, Onji M. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One 2018; 13: e0201236 [PMID: 30134787 DOI: 10.1371/journal.pone.0201236]

115 Lai MW, Hsu CW, Lin CL, Chien RN, Lin WR, Chang CS, Liang KH, Yeh CT. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatol Int 2018; 12: 456-464 [PMID: 30088198 DOI: 10.1007/s12072-018-9893-x]

116 Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fiscarco P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Pizzolotta V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggia A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology 2019; 157: 227-241. e7 [PMID: 30930022 DOI: 10.1053/j.gastro.2019.03.044]

117 Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, Yan W, Wan X, Zhu C, Xie Q, Jiang J, Wei L, Tan D, Dou X, Yu Y, Hou J, Luo X, Ning Q. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int 2019; 13: 573-586 [PMID: 31172415 DOI: 10.1007/s12072-019-09956-1]

118 Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology 2016; 63: 319-333 [PMID: 26565396 DOI: 10.1002/hep.28302]

119 Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Roviello LE, Douglas JM Jr, Janssen RS, Ward JW; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of
hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33; quiz CE1 [PMID: 17159833]

Cressey TR. Harrison L, Achalaon J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siriwachirachai T, Patyuanan C, Suriyachai P, Tierny C, Salvadori N, Chinwong D, Decker L, Tayon Y, Murphy TV, Ngo-Giang-Huong N, Siberry GK, Jourdain G; iTAT Study Team. Tenfovir Exposure during Pregnancy and Postpartum in Women Receiving Tenfovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. Antimicrob Agents Chemother 2018; 62 [PMID: 30275094 DOI: 10.1128/AAC.01686-18]

Lin Y, Liu Y, Ding G, Touqui L, Wang W, Xu N, Liu K, Zhang L, Chen D, Wu Y, Bai G. Efficacy of tenfovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep 2018; 8: 15514 [PMID: 30341345 DOI: 10.1038/s41598-018-33833-w]

Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R, Tiensong BC, Zhang H, Pan CQ. Real-world study of tenfovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther 2019; 49: 211-217 [PMID: 30506691 DOI: 10.1111/apt.15064]

Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalaon J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Lintrakul A, Varadasai S, Putyuanan C, Suriyachai P, Liampongsabuddhi P, Sangsawung S, Matanasarawut W, Buranabanjaseateun P, Puerngagoul P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasartsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N. Tenfovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med 2018; 378: 911-923 [PMID: 29514030 DOI: 10.1056/NEJMoa1708131]

of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva: World Health Organization 2020 [PMID: 32833415]

Wu ZX, Chen FS, Zhou XL, Huang Q, Zhang SA, Wu HC, Cai LR, Zeng ZY, Li VH, Li DL. Tenfovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study. Eur J Gastroenterol Hepatol 2019; 31: 832-835 [PMID: 30601336 DOI: 10.1097/MEG.0000000000001345]

Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749 [PMID: 14724827 DOI: 10.1053/gast.2003.09.026]

Huang YH, Hisao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 23773967 DOI: 10.1200/JCO.2012.48.5938]

Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017; 152: 1297-1309 [PMID: 28219601 DOI: 10.1053/j.gastro.2017.02.009]

Moezzohann L, Chen KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBeAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 2015; 22: 842-849 [PMID: 25765930 DOI: 10.1111/jvhe.12402]

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunotherapy. Blood 2019; 137: 134-146 [PMID: 30341058 DOI: 10.1182/blood-2018-04-848044]

Liu WP, Xiao XB, Xue M, Wang QQ, Wang XP, Song YQ, Zhu J. Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial. Clin Lymphoma Myeloma Leuk 2019; 19: 103-108 [PMID: 30581161 DOI: 10.1016/j.clml.2018.11.008]

Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood 2018; 131: 1987-1989 [PMID: 29490923 DOI: 10.1182/blood-2018-01-826493]

Park JW, Park KW, Cho SH, Park HS, Lee WJ, Lee DH, Kim CM. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: a report of a prospective study. Am J Gastroenterol 2005; 100: 2194-2200 [PMID: 16181368 DOI: 10.1111/j.1572-0241.2005.00232.x]

Lao XM, Wang D, Shi M, Liu G, Li S, Guo R, Yuan Y, Chen M, Li J, Zhang Y, Lin X. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res 2011; 41: 553-563 [PMID: 21615643 DOI: 10.1111/j.1872-034X.2011.00796.x]

Wang K, Jiang G, Zuo X, Ni C. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Medicine (Baltimore) 2018; 97: e10940 [PMID: 29851833 DOI: 10.1097/MD.0000000000010940]

Zhang SS, Liu JX, Zhu J, Xiao MB, Lu CH, Ni RZ, Qu LS. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-
Shah NJ et al. Recent advances in chronic hepatitis B

137 Jun BG, Kim YD, Kim SG, Kim YS, Jeong SW, Jang JY, Lee SH, Kim HS, Kang SH, Kim MY, Baik SK, Lee M, Kim JS, Choi DH, Choi SH, Suk KT, Kim DJ, Cheon GJ. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study. Jpn J Clin Oncol 2018; 49: 646-655 [PMID: 30968933 DOI: 10.1093/jjco/hyz046]

138 Liu J, Wang T, Cai Q, Sun L, Huang D, Zhou G, He Q, Wang FS, Liu L, Chen J. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res 2020; 50: 1211-1221 [PMID: 32761993 DOI: 10.1111/hepr.13553]

139 NIH. NIH strategic plan details pathway to achieving Hepatitis B cure, 2019. [cited 25 December 2020]. Available from: https://www.nih.gov/news-events/news-releases/nih-strategic-plan-details-pathway-achieving-hepatitis-b-cure

140 Hu J, Lin YY, Chen PJ, Watashi K, Wakita T. Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development. Gastroenterology 2019; 156: 338-354 [PMID: 30243619 DOI: 10.1053/j.gastro.2018.06.093]

141 Estes JD, Wong SW, Brenchley JM. Nonhuman primate models of human viral infections. Nat Rev Immunol 2018; 18: 390-404 [PMID: 29556017 DOI: 10.1038/s41577-018-0005-7]

142 Kalkeri R, Peng J, Huang C, Cai Z, Ptak RG, Suto MJ. HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007). Adv Virol 2020; 2020: 8844061 [PMID: 33110426 DOI: 10.1155/2020/8844061]

143 Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, Sadarangani M, Koff WC, Kollmann TR. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome? Trends Immunol 2020; 41: 457-465 [PMID: 32340868 DOI: 10.1016/j.it.2020.04.001]

144 Akcay IM, Katrini S, Ozdil K, Doganay GD, Doganay L. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. World J Gastroenterol 2018; 24: 3347-3360 [PMID: 30122875 DOI: 10.3748/wjg.v24.i30.3347]
